Facon T - Search Results

1

Thalidomide in patients with advanced multiple myeloma.

Yakoub-Agha I, Moreau P, Leyvraz S, Berthou C, Payen C, Dumontet C, Grosbois B, Beris P, Duguet C, Attal M, Harousseau JL, Facon T; Intergroupe Francophone du Myélome (IFM). Yakoub-Agha I, et al. Among authors: facon t. Hematol J. 2000;1(3):186-9. doi: 10.1038/sj.thj.6200031. Hematol J. 2000. PMID: 11920188 Clinical Trial.

2

Double-intensive therapy in high-risk multiple myeloma.

Harousseau JL, Milpied N, Laporte JP, Collombat P, Facon T, Tigaud JD, Casassus P, Guilhot F, Ifrah N, Gandhour C. Harousseau JL, et al. Among authors: facon t. Blood. 1992 Jun 1;79(11):2827-33. Blood. 1992. PMID: 1350228 Free article.

3

Rare occurrence of P53 gene mutations in multiple myeloma.

Preudhomme C, Facon T, Zandecki M, Vanrumbeke M, Laï JL, Nataf E, Loucheux-Lefebvre MH, Kerckaert JP, Fenaux P. Preudhomme C, et al. Among authors: facon t. Br J Haematol. 1992 Jul;81(3):440-3. doi: 10.1111/j.1365-2141.1992.tb08253.x. Br J Haematol. 1992. PMID: 1390218

4

Treatment of severe aplastic anemia with antilymphocyte globulin and androgens: a report on 33 patients.

Facon T, Walter MP, Fenaux P, Morel P, Dupriez B, Gardin C, Jouet JP, Bauters F. Facon T, et al. Ann Hematol. 1991 Aug;63(2):89-93. doi: 10.1007/BF01707279. Ann Hematol. 1991. PMID: 1912037

5

Treatment of relapsed acute myeloid leukemia with idarubicin and intermediate-dose cytarabine.

Harousseau JL, Reiffers J, Hurteloup P, Milpied N, Guy H, Rigal-Huguet F, Facon T, Dufour P, Ifrah N. Harousseau JL, et al. Among authors: facon t. J Clin Oncol. 1989 Jan;7(1):45-9. doi: 10.1200/JCO.1989.7.1.45. J Clin Oncol. 1989. PMID: 2642539 Clinical Trial.

6

Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis.

Laï JL, Zandecki M, Mary JY, Bernardi F, Izydorczyk V, Flactif M, Morel P, Jouet JP, Bauters F, Facon T. Laï JL, et al. Among authors: facon t. Blood. 1995 May 1;85(9):2490-7. Blood. 1995. PMID: 7537117 Free article. Review.

7

Significance of circulating plasma cells in multiple myeloma.

Zandecki M, Facon T, Preudhomme C, Canis F, Izydorczyk V, Lovi V, Hammad M, Bauters F, Cosson A. Zandecki M, et al. Among authors: facon t. Leuk Lymphoma. 1994 Aug;14(5-6):491-6. doi: 10.3109/10428199409049709. Leuk Lymphoma. 1994. PMID: 7812210

8

Prognostic factors in low tumour mass asymptomatic multiple myeloma: a report on 91 patients. The Groupe d'Etudes et de Recherche sur le Myélome (GERM).

Facon T, Menard JF, Michaux JL, Euller-Ziegler L, Bernard JF, Grosbois B, Daragon A, Azais I, Courouble Y, Kaplan G, et al. Facon T, et al. Am J Hematol. 1995 Feb;48(2):71-5. doi: 10.1002/ajh.2830480201. Am J Hematol. 1995. PMID: 7847344

9

[Correlation between the serum level of soluble CD16 and the staging of myeloma: study of 214 serums].

Mathiot C, Grosbois B, Teillaud JL, Tartour E, Mosseri V, Euller-Ziegler L, Daragon A, Michaux JL, Facon T, Bernard JF, et al. Mathiot C, et al. Among authors: facon t. Rev Med Interne. 1993;14(10):960. doi: 10.1016/s0248-8663(05)80078-5. Rev Med Interne. 1993. PMID: 8009056 French.

10

Improved cytogenetic analysis of bone marrow plasma cells after cytokine stimulation in multiple myeloma: a report on 46 patients.

Facon T, Lai JL, Nataf E, Preudhomme C, Zandecki M, Hammad M, Wattel E, Jouet JP, Bauters F. Facon T, et al. Br J Haematol. 1993 Aug;84(4):743-5. doi: 10.1111/j.1365-2141.1993.tb03155.x. Br J Haematol. 1993. PMID: 8217836

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

414 results

Search Page